Greenwich LifeSciences, Inc.: Business Overview, Financials & Competitive Analysis

Greenwich LifeSciences, Inc. Overview

Greenwich LifeSciences is a clinical-stage biopharmaceutical company developing GP2, an immunotherapy candidate designed to prevent breast cancer recurrence in HER2-positive patients who have undergone surgery. The company's lead program, FLAMINGO-01, is a Phase III global trial spanning 150+ clinical sites across the US and Europe, with interim analysis planned for a 70% reduction in metastatic recurrence.

Strategic Profile

The company positions GP2 as a potential breakthrough therapy with Phase IIb data showing 80%+ reduction in recurrence rates, significantly exceeding the ~50% achieved by existing HER2-targeted therapies like Herceptin and Kadcyla. With FDA approval of the first commercial manufacturing lot received in January 2026 and recent capital raises maintaining ~$12.5M in cash, Greenwich LifeSciences is executing a capital-efficient approach while advancing toward pivotal trial completion.

Competitive Landscape

Greenwich LifeSciences competes in the HER2-targeted breast cancer therapeutic space against established players with approved recurrence-prevention therapies. Direct competitors include Roche/Genentech (Herceptin/trastuzumab), Eli Lilly (Kadcyla/ado-trastuzumab), and other immuno-oncology companies developing preventative approaches. GP2's proposed mechanism and Phase IIb efficacy data position it as a potential best-in-class candidate if Phase III validation succeeds.

Industry Context

Greenwich LifeSciences, Inc. operates in Biopharmaceutical / Immuno-Oncology.

Key facts

Headquarters: Stafford, Texas, United States · Revenue: $0